Immunotherapy for Renal Cell Carcinoma: Types, Side Effects and More

Quick note: This article is for educationnot personal medical advice. Renal cell carcinoma (RCC) treatment choices are highly individualized, so use this as a smart conversation-starter with your oncology team.

Why immunotherapy matters in renal cell carcinoma

Renal cell carcinoma is the most common type of kidney cancer in adults, and for years it had a reputation for being stubborn about traditional chemotherapy.
The plot twist? RCC can be surprisingly “immune-aware.” That’s why immunotherapytreatments that help your immune system recognize and attack cancerhas become
one of the biggest game-changers in kidney cancer care.

Immunotherapy can be used in different moments of the RCC journey:

• After surgery (adjuvant therapy) to lower the risk of the cancer coming back in certain higher-risk cases.
• For advanced or metastatic RCC to shrink tumors, slow growth, and in some people, produce long-lasting control.
• In clinical trials for newer immune strategies or for RCC subtypes where the best approach is still evolving.

How immunotherapy works (without the PhD headache)

Your immune system is basically a security team. It patrols, checks IDs, and removes threats. Cancer is sneakyit can disguise itself or press the “do not disturb”
buttons that keep immune cells from attacking. Immunotherapy helps undo those tricks.

In RCC, the most widely used immunotherapies today are immune checkpoint inhibitors. Think of checkpoints as brakes on immune cells.
Some cancers exploit those brakes. Checkpoint inhibitors release themcarefullyso immune cells can do their job.

Types of immunotherapy used for RCC

1) Immune checkpoint inhibitors (the modern backbone)

Checkpoint inhibitors used in RCC mainly target two pathways:

• PD-1 / PD-L1 inhibitors (often called “PD-1 blockers”): help T cells stay active against cancer.
• CTLA-4 inhibitors: affect early T-cell activation and can amplify immune response (often used in combination).

Common checkpoint inhibitors you’ll see in RCC discussions include:

• Nivolumab (PD-1 inhibitor)
• Pembrolizumab (PD-1 inhibitor)
• Avelumab (PD-L1 inhibitor)
• Ipilimumab (CTLA-4 inhibitor; typically paired with nivolumab in RCC)

Checkpoint inhibitors are used either alone in select settings or, more commonly, in combinations (more on that below).

2) Cytokines (the “classic” immunotherapystill around, but selective)

Before checkpoint inhibitors took center stage, RCC was one of the cancers most associated with cytokine therapy:

• Interleukin-2 (IL-2) (aldesleukin): can produce rare but durable complete responses in a small subset of patients.
• Interferon-alfa: used far less now, historically part of RCC treatment.

The catch: high-dose IL-2 can cause significant side effects and usually requires treatment at experienced centers.
Today, it’s generally considered in carefully selected situations rather than as a default first pick.

3) “Next-wave” immunotherapy (mostly in clinical trials)

Researchers are actively studying newer immune approaches in RCC, such as novel antibody combinations, immune-stimulating molecules,
personalized vaccines, and other targeted immune strategies. If you hear “bispecific,” “engineered cytokine,” or “personalized vaccine,”
you’re usually in clinical-trial territory. Clinical trials can be especially important for non–clear cell RCC subtypes, where data can be thinner.

Immunotherapy regimens for advanced (metastatic) RCC

In metastatic RCCespecially clear cell RCC, the most common subtypeimmunotherapy is frequently used as part of a combination strategy.
The goal is to balance two things:

• Depth and speed of response (how quickly tumors shrink and how much)
• Durability (how long the benefit lasts)

Option A: IO + IO (two immunotherapies)

The best-known IO+IO combination in RCC is:
nivolumab + ipilimumab.

Why doctors consider it: it can produce durable responses in a subset of patients, including complete responses in some cases.
It may be especially appealing when the long-term “tail” of benefit is a priority.

Option B: IO + targeted therapy (immunotherapy plus a VEGF-targeted TKI)

Many first-line standards pair an immune checkpoint inhibitor with a targeted therapy that blocks tumor blood vessel signaling
(often called a VEGF/VEGFR tyrosine kinase inhibitor, or TKI). Common IO+TKI combinations used in RCC include:

• Pembrolizumab + axitinib
• Nivolumab + cabozantinib
• Pembrolizumab + lenvatinib
• Avelumab + axitinib (used in some settings; practice patterns vary)

Why doctors consider IO+TKI: these combinations often produce high response rates and can be useful when rapid tumor shrinkage
is important (for example, symptoms from bulky disease).

So… which combination is “best”?

If you were hoping for a single winner, RCC would like to apologize for being complicated.
Choice often depends on:

• Risk category and disease features (including whether the cancer is aggressive or symptomatic)
• Side-effect considerations (autoimmune history, organ function, blood pressure issues, etc.)
• Patient goals (prioritizing long-term durability vs. rapid shrinkage)
• Convenience and monitoring (infusion schedule, pill burden, lab checks)

Immunotherapy after surgery: adjuvant treatment in RCC

Immunotherapy isn’t only for metastatic disease. For certain people with RCC at intermediate-high or high risk of recurrence
after nephrectomy (kidney surgery), adjuvant pembrolizumab is an FDA-approved option intended to lower recurrence risk.

In plain English: if your cancer was removed surgically but had features that make doctors worry it could come back, a year of immunotherapy
may be considered to improve the odds.

What to expect: how immunotherapy is given and monitored

Most checkpoint inhibitors are given by IV infusion in an outpatient oncology clinic. Appointments typically include:

• Pre-treatment symptom check (“Any new cough? Diarrhea? Rash? Fatigue that feels different?”)
• Lab monitoring (blood counts, liver enzymes, kidney function, thyroid tests, and others as needed)
• The infusion itself (often 30–60 minutes, depending on the drug and protocol)
• Periodic imaging scans to assess response

If you’re on an IO+TKI combo, you’ll also have a daily oral medication, plus monitoring for targeted-therapy effects like
high blood pressure or hand-foot skin irritation.

Side effects of immunotherapy for RCC

Immunotherapy side effects aren’t like traditional chemo side effects. Instead of “everything is miserable all at once,”
checkpoint inhibitors can cause immune-related adverse eventsyour immune system getting a little too enthusiastic
and inflaming normal organs.

Common (often manageable) side effects

• Fatigue
• Skin changes (itching, rash)
• Mild diarrhea or stomach upset
• Joint or muscle aches
• Changes in appetite

More serious immune-related side effects (less common, but important)

These can affect nearly any organ system. Examples include:

• Gut: colitis (persistent diarrhea, abdominal pain)
• Liver: hepatitis (abnormal liver tests, sometimes yellowing of skin/eyes)
• Lungs: pneumonitis (new or worsening cough, shortness of breath)
• Hormone glands: thyroid or pituitary inflammation (fatigue, weight changes, heat/cold intolerance, headaches)
• Kidneys: nephritis (changes in kidney labs)
• Skin: severe rash (rare but can be significant)

The key idea: early reporting matters. Many immune-related side effects respond well when recognized promptly.
Waiting it out rarely wins an award.

Side effects of cytokine therapy (IL-2) in RCC

IL-2 works differently and can cause intense, rapid side effects that require specialized monitoring. This is a major reason
it’s reserved for select cases at experienced centers.

How side effects are managed (the practical overview)

Management depends on the organ involved and the severity. In general, clinicians may:

• Pause immunotherapy temporarily
• Use anti-inflammatory medicines (often corticosteroids) for moderate-to-severe immune reactions
• Refer to specialists (GI, pulmonology, endocrinology, nephrology) depending on the issue
• Restart immunotherapy cautiously in some situations, or stop it permanently in others

If you remember one thing, make it this: don’t self-diagnose immune side effects. Call your oncology team.
They’d rather hear from you “too early” than “after three weeks of heroic suffering.”

Who is (and isn’t) a good candidate for immunotherapy?

Many people with advanced clear cell RCC are candidates for immunotherapy-based combinations, but special caution applies in certain scenarios:

• Autoimmune diseases (like lupus or inflammatory bowel disease): immunotherapy may flare symptoms; sometimes it’s still used with careful planning.
• Organ transplant recipients: checkpoint inhibitors can increase the risk of organ rejectionthis requires specialized risk-benefit discussion.
• Significant lung disease: pneumonitis risk may be more concerning.
• Frailty or complex medical issues: sometimes a simpler regimen is preferred.

Specific examples: what decision-making can look like

Example 1: Need for fast shrinkage

A patient has metastatic clear cell RCC with symptoms from tumor burden (pain, reduced appetite, or organ pressure).
The oncology team may lean toward an IO+TKI combination because the targeted therapy component can help drive quicker responses
in many patientswhile the immunotherapy contributes durability.

Example 2: Prioritizing long-term durability

Another patient has metastatic disease but stable symptoms, and they strongly value the possibility of a long-lasting response
even if it comes with a higher chance of immune side effects. The team may discuss nivolumab + ipilimumab as a potential fit,
reviewing monitoring plans and what to watch for.

Example 3: Post-surgery, higher risk of recurrence

After nephrectomy, pathology shows features associated with a higher chance of recurrence. The patient and clinician discuss
adjuvant pembrolizumabincluding the potential benefit, the commitment (often about a year of therapy),
and the possibility of immune-related side effects even though there’s no visible cancer on scans.

Questions to ask your care team

• What is my RCC subtype (clear cell vs non–clear cell) and stage?
• What treatment goal fits me best right now: shrinkage, long-term control, symptom relief, or recurrence prevention?
• Which immunotherapy regimen are you recommending, and why?
• What side effects should I report immediately?
• How often will I have labs and scans?
• If immunotherapy stops working, what are the next steps?
• Should I consider a clinical trial?

Real-world experiences: what people often notice (about )

If you ask patients what immunotherapy “feels like,” the most common answer is: “It’s not what I expected.”
Many people walk into treatment bracing for the classic chemo storylineconstant nausea, dramatic hair loss, feeling wiped out 24/7.
With checkpoint inhibitors, the day-to-day experience can look very different.

A typical infusion visit is often surprisingly uneventful. People show up, get checked in, answer symptom questions, have labs drawn,
and sit for the infusion. Some bring a book. Some bring snacks like it’s an airline flight. A lot of people bring a loved one,
partly for company and partly because cancer paperwork is basically a second job. The “action” tends to happen in the weeks between visits,
which is why oncologists and nurses emphasize tracking changesespecially anything new that doesn’t behave like a normal cold or stomach bug.

Fatigue is the big one patients talk about. Not always the “I need a nap” fatigue, but sometimes the “my battery doesn’t hold a charge” fatigue.
People often describe learning to pace themselves: doing errands in shorter bursts, planning rest after appointments,
and giving themselves permission to say no without writing a five-paragraph apology.
Some notice mild aches, itchiness, or changes in appetite that come and go.

The tricky part is that immune-related side effects can be subtle at first. Patients often describe a moment of uncertainty:
“Is this just something I ate?” or “Am I getting sick?” That’s why experienced oncology teams teach a simple rule:
if symptoms are persistent, unusual for you, or getting worsecall. Many people say they were relieved to learn that reporting symptoms
isn’t “complaining”; it’s part of doing immunotherapy safely. Early action can prevent a small problem from becoming a bigger one.

Caregivers often have their own perspective: immunotherapy can look “easy” from the outside because the patient might still be working,
attending school events, or doing normal routines. But the emotional load can be heavywaiting for scan results, watching for symptoms,
and adjusting family logistics around appointments. A lot of families find it helpful to keep a shared notes app with symptoms,
questions for the next visit, and medication changes, so nothing gets lost in the blur of everyday life.

Clinicians often describe immunotherapy as a long game. Some patients see tumor shrinkage quickly; others see slower changes,
and occasionally scans can look confusing early on. The most reassuring real-world takeaway you’ll hear from many oncology teams is:
you are not expected to “tough it out” alone. Immunotherapy works best when patients and care teams operate like a coordinated squad
sharing updates, responding early to side effects, and adjusting the plan when needed. In RCC, that partnership is part of the treatment.

Conclusion

Immunotherapy has reshaped renal cell carcinoma treatmentespecially for advanced clear cell RCC and for certain higher-risk patients after surgery.
Today’s checkpoint inhibitors (often paired with targeted therapy or combined together) can shrink tumors, slow progression, and in some cases
deliver long-lasting control. The trade-off is a unique side-effect profile: immune-related inflammation that requires attention and early reporting.
If you’re facing RCC decisions, focus on two things: (1) choosing a regimen that matches your disease features and life priorities,
and (2) building a clear plan with your oncology team for monitoring and side-effect management.